Vilaprisan phase 2B trial: a timely efficacy and safety study of a novel selective progesterone receptor modulator for nonsurgical management of uterine fibroids

被引：3
|
作者：
Magnay, Julia L. [1 ]
机构：
[1] Keele Univ, Inst Sci & Technol Med, Stoke On Trent, Staffs, England
来源：
FERTILITY AND STERILITY | 2019年 / 111卷 / 02期
关键词：
D O I：
10.1016/j.fertnstert.2018.10.033
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：249 / 250
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2
    Gemzell-Danielsson, Kristina
    Heikinheimo, Oskari
    Zatik, Janos
    Poka, Robert
    Rechberger, Tomasz
    Hudecek, Robert
    Petersdorf, Kathrin
    Ramirez, Francisco
    Faustmann, Thomas
    Groettrup-Wolfers, Esther
    Seitz, Christian
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2020, 252 : 7 - 14
  • [2] Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study
    Bradley, Linda D.
    Singh, Sukhbir S.
    Simon, James
    Gemzell-Danielsson, Kristina
    Petersdorf, Kathrin
    Groettrup-Wolfers, Esther
    Ren, Xiaowei
    Zvolanek, Michal
    Seitz, Christian
    FERTILITY AND STERILITY, 2019, 111 (02) : 240 - 248
  • [3] Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate
    Donnez, Jacques
    Donnez, Olivier
    Dolmans, Marie-Madeleine
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (12) : 1679 - 1686
  • [4] Pharmacodynamic Effects and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Healthy Women
    Rohde, Beate
    Seitz, Christian
    Kaiser, Andreas
    Schultze-Mosgau, Marcus
    Schutt, Barbara
    REPRODUCTIVE SCIENCES, 2015, 22 : 88A - 88A
  • [5] Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment
    Schultze-Mosgau, Marcus-Hillert
    Lasseter, Kenneth C.
    Marbury, Thomas
    Loewen, Stephanie
    Riecke, Kai
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (08): : 1030 - 1038
  • [6] EFFICACY AND SAFETY OF THE SELECTIVE PROGESTERONE RECEPTOR MODULATOR (PRM) VILAPRISAN: INTEGRATED ANALYSIS OF PHASE 2 ASTEROID 1 AND 2 STUDIES.
    Danielsson, K. Gemzell
    Bradley, L. D.
    Ahlers, C.
    Faustmann, T.
    Petersdorf, K.
    Zvolanek, M.
    Groettrup-Wolfers, E.
    Seitz, C.
    FERTILITY AND STERILITY, 2018, 110 (04) : E135 - E135
  • [7] EFFICACY AND SAFETY OF THE SELECTIVE PROGESTERONE RECEPTOR MODULATOR (PRM) VILAPRISAN: A SUB-ANALYSIS OF THE ASTEROID 1 TRIAL BY ETHNICITY
    Bradley, L. D.
    Groettrup-Wolfers, E.
    Zvolanek, M.
    Petersdorf, K.
    Seitz, C.
    FERTILITY AND STERILITY, 2018, 110 (04) : E62 - E62
  • [8] EFFICACY AND SAFETY OF THE SELECTIVE PROGESTERONE RECEPTOR MODULATOR (PRM) VILAPRISAN-24-WEEK OUTCOMES FROM ASTEROID 2
    Danielsson, K. Gemzell
    Ramirez, F.
    Petersdorf, K.
    Faustmann, T.
    Groettrup-Wolfers, E.
    Seitz, C.
    FERTILITY AND STERILITY, 2018, 110 (04) : E62 - E62
  • [9] Mass Balance Study of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Healthy Volunteers.
    Schultze-Mosgau, Marcus
    Hochel, Joachim
    Prien, Olaf
    Zimmermann, Torsten
    Brooks, Ashley
    Rottmann, Antje
    REPRODUCTIVE SCIENCES, 2016, 23 : 166A - 166A
  • [10] Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation
    Sutter, Gabriele
    Frei, Matthias
    Schultze-Mosgau, Marcus-Hillert
    Petersdorf, Kathrin
    Seitz, Christian
    Ploeger, Bart A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (02) : 734 - 741
12345